Sunitinib multi target TKI

Description Results NMA

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sunitinib 37.5 mg/day plus erlotinib 150 mg/day continuously in 4-week cycles (n=-9)

vs.

placebo plus erlotinib (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

phase II phase II

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint: OS

FU duration:

phase III

PFS 0.42 [0.32; 0.55]

OS 0.82 [0.67; 1.00]

repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) (n=375)

vs.

interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). (n=375)

Sample size: 375/375

Primary endpoint: PFS

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: